We in the market like to talk about risk a lot, and the recent selloff in high-flying stocks was no different. How many times did you read (or did I write) that the market’s riskiest stocks sold off? But when you really dig into performance, you’ll notice that hasn’t really been the case during the recent plunge in “risky” stocks.
This chart shows the performance of the iShares MSCI USA Momentum Factor ETF (MTUM) (in blue) and the PowerShares S&P 500 High Beta ETF (SPHB) (in yellow):
As you can see, since March 1, the iShares MSCI USA Momentum Factor ETF, which holds stocks like Facebook (FB) and Gilead Sciences (GILD), has dropped 3.9%, while the PowerShares S&P 500 High Beta ETF, which counts Nabors Industries (NBR) and First Solar (FSLR) among its largest positions, is down just a touch during the same period.
Hot Long Term Companies To Invest In Right Now: Constellium NV (CSTM)
Constellium N.V., formerly Constellium Holdco BV, is a Netherlands-based company, which is engaged in the manufacture of aluminum products and solutions. The Company is a supplier of such sectors as: aerospace, automotive and packaging. Constellium Holdco BV offers plates, sheet and coil, precision casting, cockpit carriers for vehicles, vehicle safety components, profiles, as well as tubes and bars, among others. Its main customers include: Airbus, Boeing, Embraer, Audi, BMW, Citroen, Renault, Mercedes Benz, Jaguar and others. The Company is active domestically and abroad, including North America, Europe and Asia. Advisors' Opinion:- [By Jan-e- Alam]
Constellium (NYSE: CSTM ) is a downstream aluminum producer engaged in the design, manufacture, and sale of specialty rolled and extruded aluminum products. The Netherlands-based company, which offers its products primarily to the aerospace, automotive, and packaging industries, is a world leader in the manufacturing of high-quality aluminum products and solutions.
- [By Laura Brodbeck]
Thursday
Earnings Expected From: Abercrombie & Fitch (NYSE: ANF), Dollar General (NYSE: DG), Genesco (NYSE: GCO), Constellium NV (NYSE: CSTM) Economic Releases Expected: Japanese retail sales, Japanese industrial production, Japanese unemployment rate, British consumer confidence, U.S. GDP, eurozone consumer confidence, German unemployment rate, Spanish GDPFriday
- [By GuruFocus]
George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated
Top Healthcare Technology Companies To Own For 2014: Isramco Inc.(ISRL)
Isramco, Inc., together with its subsidiaries, engages in the acquisition, development, production, and exploration of onshore oil and natural gas properties in the United States. It owns various working interests in oil and gas wells in Louisiana, Texas, New Mexico, Oklahoma, Wyoming, Utah, and Colorado; and operates approximately 589 wells principally in Texas and New Mexico. The company sells its oil and natural gas products to independent marketers, oil and natural gas companies, and gas pipeline companies. As of December 31, 2010, its estimated total proved reserves were approximately 9,031 thousand barrels of oil equivalent, which included 3,318 thousand barrels of oil, and 23,701 million cubic feet of natural gas, and 1,763 thousand barrels of natural gas liquids. The company was founded in 1982 and is based in Houston, Texas.
Advisors' Opinion:- [By Rich Duprey]
Yet when you think about it, there should be oil there. It's been found on all sides of Israel. Total� (NYSE: TOT ) �found�oil north of the Sinai Peninsula in the 1980s, but the wells subsequently went dry;�Isramco� (NASDAQ: ISRL ) found oil off the coast of Tel Aviv, but never enough to make it profitable; and�Noble found a large gas deposit in the Tamar field of the Levant basin. Several Israeli companies have also found oil and gas, but Zion keeps striking out.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Isramco (Nasdaq: ISRL ) , whose recent revenue and earnings are plotted below. - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Isramco (Nasdaq: ISRL ) , whose recent revenue and earnings are plotted below.
Top Healthcare Technology Companies To Own For 2014: OmniVision Technologies Inc.(OVTI)
OmniVision Technologies, Inc. designs, develops, and markets semiconductor image-sensor devices. The company offers CameraChip image sensors, which are single-chip solutions that integrate various functions, such as image capture, image processing, color processing, signal conversion, and output of a processed image or video stream for use in various consumer and commercial mass-market applications; and CameraCube imaging devices that are image sensors with integrated wafer-level optics. It also provides companion chips used to connect its image sensors to various interfaces, including the universal serial bus and other industry standard interfaces; and companion digital signal processors that perform compression in standardized still photo and digital video formats. In addition, the company designs and develops software drivers for Linux, Mac OS, and Microsoft Windows, as well as for embedded operating systems, such as Blackberry OS, Palm OS, Symbian, Windows CE, Windows Embedded, and Windows Mobile. Its products are used in mobile phones, notebooks, Webcams, digital still and video cameras, commercial and security and surveillance, and automotive and medical applications, as well as in entertainment devices. The company sells its products directly to original equipment manufacturers and value added resellers, as well as indirectly through distributors worldwide. OmniVision Technologies, Inc. was founded in 1995 and is based in Santa Clara, California.
Advisors' Opinion:- [By Evan Niu, CFA]
Once upon a time, I was also an OmniVision (NASDAQ: OVTI ) bull, thinking the image sensor specialist's lead in backside-illuminated technology gave it a substantial leg up against the competition. When OmniVision lost the iPhone 4S primary camera spot to Sony,�that was just the first sign that things may never be the same. The company subsequently lost the iPhone 5 primary sensor, also to Sony. HTC has gone with STMicroelectronics�for the "UltraPixel" sensor in its One flagship (OmniVision sources the secondary sensor), which lends to the idea that BSI sensors are becoming commoditized. Goodbye, pricing power. I gave up on OmniVision long ago.
- [By Rich Bieglmeier]
OmniVision Technologies, Inc. (OVTI) plans to release its financial results for the second quarter of fiscal year 2014 on Tuesday, December 03, 2013, shortly after the market closes.� The Company plans to host a conference call to review the results and management's outlook for future periods at 5 p.m. (ET) that day.
- [By Paul Ausick]
Stocks on the move: Apache Corp. (NYSE: APA) is up 8.9% at $85.66 after a $3.1 billion asset sale to Sinopec. OmniVision Technologies Inc. (NASDAQ: OVTI) is down 16.1% at $15.45 after warning on earnings due to lower sales of smartphones. E-Commerce China Dangdang Inc. (NYSE: DANG) is down 10.1% at $7.80 on a downgrade from JPMorgan.
- [By Wallace Witkowski]
Shares of OmniVision (OVTI) �fell 13% to $13.89 on heavy volume after the company said it expects adjusted fiscal third-quarter earnings of 28 cents to 44 cents a share on revenue of $310 million to $340 million. Analysts surveyed by FactSet expect earnings of 43 cents a share on revenue of $399.5 million.
Top Healthcare Technology Companies To Own For 2014: Mylan Inc (MYL)
Mylan Inc. (Mylan), incorporated in 1970, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies. Through Mylan Laboratories Limited, an Indian subsidiary, it manufactures and supply active pharmaceutical ingredient (API) for its own products and pipeline, as well as for third parties. On December 23, 2011, Mylan completed the acquisition of rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline�� Advair Diskus and Seretide Diskus incorporating Pfizer Inc.��, (Pfizer) dry powder inhaler delivery platform (the Respiratory Delivery Platform). In February 2012, Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to the Company.
As of December 31, 2011, Mylan marketed a global portfolio of approximately 1,100 different products covering a range of therapeutic categories. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, it focuses on transdermal patches, high potency formulations, injectables, controlled release and respiratory delivery products. Mylan operates in two segments: Generics and Specialty. Its revenues are derived from the sale of generic and branded generic pharmaceuticals, specialty pharmaceuticals and API. Its generic pharmaceutical business is conducted in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA), and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited, which is included within the Asia Pacific region in its Generi! cs segment. Its specialty pharmaceutical business is conducted by Dey Pharma, L.P. (Dey).
Generics Segment
The Company sales in the United States are derived through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through Mylan Institutional (MI). MPI�� net revenues are derived from the sale of solid oral dosage and transdermal patch products. MI�� net revenues are derived from the sale of its unit dose and injectable product offerings. In the United States, it has product portfolios consisting of approximately 340 products, of which approximately 305 are in capsule or tablet form in an aggregate of approximately 740 dosage strengths. Included in these totals are approximately 40 extended release products in a total of approximately 105 dosage strengths. Also included in it�� the United States product portfolio are four transdermal patch products in a total of 18 dosage strengths, which are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.
The Company�� North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 115 products in an aggregate of approximately 250 dosage strengths. Its generic pharmaceutical sales in EMEA are generated by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries.
In France, through the Company�� subsidiary Mylan S.A.S., it markets a retail portfolio of approximately 215 products in an aggregate of approximately 455 dosage strengths. In Italy, it markets through its subsidiary Mylan S.p.A. a portfolio of approximately 150 products in an aggregate of approximately 285 dosage strengths. In Italy, it h! as market! share, based on value and volume, in the company-branded generic retail prescription market. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 100 products in an aggregate of approximately 220 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 150 products in an aggregate of approximately 330 dosage strengths. In the United Kingdom, it offers a product portfolio of approximately 175 products in an aggregate of approximately 315 dosage strengths. It markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, New Zealand, India, Japan and Taiwan.
In Australia, the Company offers a portfolio of approximately 170 products in an aggregate of approximately 440 dosage strengths. Mylan Seiyaku, its wholly owned Japanese subsidiary, offers a portfolio of more than 380 products in an aggregate of approximately 500 dosage strengths. At Mylan Laboratories Limited, its dosage business produces antiretroviral (ARV) products, which are sold outside of India, and other finished dosage form (FDF) products, which are sold to third parties by other Mylan operations globally. In addition, Mylan Laboratories Limited offers a line of FDF products in the ARV market and manufactures non-ARV FDF products that are marketed by Mylan.
Specialty Segment
The Company�� specialty pharmaceutical business is conducted through Dey. Dey�� portfolio consists of branded specialty injectable, nebulized and transdermal products for life-threatening conditions. Dey�� revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the United States and internationally.
Advisors' Opinion:- [By Ben Levisohn]
Mylan (MYL) has dropped 0.9% to $47.50 after the generic-drug maker missed analyst earnings forecasts and lowered the top end of its revenue and profit guidance.
Top Healthcare Technology Companies To Own For 2014: China TechFaith Wireless Communication Technology Limited(CNTF)
China Techfaith Wireless Communication Technology Limited, together with its subsidiaries, operates as an original developed products provider that is focused on the original design and sale of mobile phones in the People's Republic of China and internationally. Its original developed products include multimedia phones, and dual mode dual card handsets of multiple wireless technology combinations; Windows-based smartphones and Pocket PC phones; and handsets with interactive online gaming and professional game terminals with phone functionality. The company also provides gaming content to the motion, mobile, and online PC gaming markets through its Web sites. In addition, it develops Middleware Application MMI/UI software packages on 2G/2.5G, 3G, and 3.5G communication technologies. The company was founded in 2002 and is based in Beijing, the People's Republic of China.
Advisors' Opinion:- [By Bryan Murphy]
When traders think of exciting story stocks, China Techfaith Wireless Comm. Tech. Ltd (NASDAQ:CNTF) probably doesn't show up on anybody's list. The maker of mobile handsets doesn't exactly have the same kind of market share that, say an Apple (AAPL) or a Samsung might enjoy, and probably won't anytime soon. Yet, there's something about CNTF that's compelling enough to merit taking a shot on heading into 2014.
Top Healthcare Technology Companies To Own For 2014: Cardiome Pharma Corporation(CRME)
Cardiome Pharma Corp., a life sciences company, engages in developing proprietary drugs to treat or prevent cardiovascular and other diseases. The company offers BRINAVESS, a product approved for marketing in the European Union, Iceland, and Norway for the conversion of recent onset atrial fibrillation to sinus rhythm in adults. It also has clinical programs, which focuses on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. The company has a phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C that completed phase I clinical trials for the treatment of infectious disease. In addition, Cardiome Pharma Corp. has pre-clinical projects that focus on cardiac diseases, ion channel conditions, and other indications. It also has a collaboration and license agreement with Merck & Co., Inc. (Merck), for the development and commercialization of vernakalant; and Astellas Pharma US, Inc. t o develop, make, and sell intravenous or injectable formulations of vernakalant in North America. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.
Advisors' Opinion:- [By Bryan Murphy]
Back on March 13th I penned some less-than-well-received thoughts on Cardiome Pharma Corp. (NASDAQ:CRME). Basically, I was warning that CRME was just one stumble away from a fairly significant selloff. Given that so many traders were a fan of the biotech stock at the time, merely posing the possibility of a dip was something of a threat to my life and limb.
- [By John Udovich]
The biotech sector along with small cap biotech stocks Cardiome Pharma Corp (NASDAQ: CRME), Oncolytics Biotech, Inc (NASDAQ: ONCY), Vital Therapies Inc (NASDAQ: VTL) and TNI BioTech (OTCMKTS: TNIB) have all been producing their share of news this week for investors and traders alike to trade on. Moreover and while some 42 ��ife sciences��companies have gone public raising about $3 billion from investors so far this year, there are a growing number of biotechs pulling the plug on upcoming IPOs who are citing market conditions. With that in mind, here is a look at important news from the biotech sector and small cap biotech stocks this week:
- [By Roberto Pedone]
One under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Cardiome Pharma (CRME), which engages in the discovery, development and commercialization of therapies that enhance the health of patients. This stock has been on fire over the last three months, with shares up sharply by 43%.
If you take a look at the chart for Cardiome Pharma, you'll notice that this stock has been trading range bound for the last month or so, with shares moving between $5.85 on the downside and $7.15 on the upside. Shares of CRME have now started to bounce higher off that big support level near $6 a share and it's quickly moving within range of triggering a big breakout trade above some key near-term overhead resistance levels.
Traders should now look for long-biased trades in CRME if it manages to break out above some near-term overhead resistance levels at $6.95 to its 52-week high at $7.15 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 123,602 shares. If that breakout triggers soon, then CRME will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $9 to $10 a share.
Traders can look to buy CRME off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $6 or $5.85 or near its 50-day moving average of $5.63 a share. One can also buy CRME off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top Healthcare Technology Companies To Own For 2014: InfoSonics Corp(IFON)
InfoSonics Corporation engages in the design, development, sourcing, and sale of wireless handsets and accessories in Latin America and the Asia Pacific. The company offers a line of entry-level, mid-tier, and high-end products under the verykool brand name. It contracts with electronic manufacturing services providers to manufacture its branded products. The company?s customers include carriers, agents, distributors, resellers, and original equipment manufacturers. InfoSonics Corporation was founded in 1994 and is headquartered in San Diego, California.
Advisors' Opinion:- [By Bryan Murphy]
Looking for some new trading ideas? Start by putting Arrowhead Research Corp. (NASDAQ:ARWR) and InfoSonics Corporation (NASDAQ:IFON) on your watchlist... though not yet in your portfolio. Though both IFON and ARWR have laid the foundation for a rally, neither has gotten above their final humps. Here's a closer look at what it's going to take.
- [By Monica Gerson]
Infosonics (NASDAQ: IFON) shares jumped 22.64% to $2.06. Infosonics shares have jumped 170.97% over the past 52 weeks, while the S&P 500 index has gained 23.35% in the same period.
No comments:
Post a Comment